INHALED BECLOMETHASONE TO PREVENT CHRONIC LUNG DISEASE

这项研究旨在阐明新生儿 慢性肺部疾病的发生，并测试其容量和安全性 吸入糖皮质激素预防慢性肺部疾病的过程和 它对生长和发育的伴随影响。这将是 通过一项随机、安慰剂对照的临床试验完成 吸入皮质类固醇，二丙酸倍氯米松，用于以下婴儿 出生体重1251克，妊娠33周以下，3至14岁 天龄时，继续需要机械通风。倍氯米松 将通过使用麻醉袋的手动呼吸机给药 一种带有间隔装置的可用于28天治疗的计量吸入器 句号。

This Study has been designed to elucidate mechanisms by which neonatal chronic lung disease occurs, and to test the capacity and safety of inhaled glucocorticoid to prevent the process of chronic lung disease and its accompanying effects on growth and development. This will be accomplished through a randomized, placebo controlled clinical trial of inhaled corticosteroid, beclomethasone dipropionate, in infants less than 1251 gm birth weight and less than 33 weeks gestation who, at 3 to 14 days of age, continue to require mechanical ventilation. Beclomethasone will be administered via manual ventilation with an anesthesia bag using a metered dose inhaler with a spacer device for a 28 day treatment period.